Status:
COMPLETED
Immunoglobulin Gene Rearrangement and Repair in Healthy Donors
Lead Sponsor:
University Hospital, Limoges
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
B-cells ensure humoral immune response against antigens (Ag) thanks to their receptor (BCR). V(D)J rearrangement, somatic hypermutation, immunoglobulin (Ig) class switch and locus suicide recombinatio...
Eligibility Criteria
Inclusion
- healthy volunteers aged between 18 and 70
- volunteers free from lymphoid hemopathy, immune deficiency and autoimmune disease.
- 3 categories : volunteers between 18 and 34 years of age, volunteers between 35 and 50 years of age, volunteers between 51 and 69 years of age.
Exclusion
- any recent vaccination (\< 4 weeks)
- tumoral pathology
- lymphoïd hemopathy
- immune deficiency
- autoimmune disease
- transplanted patients
- inflammatory / systemic diseases
- hypersensitivity or allergies
- treatments likely to modify the immune response :
- calcineurin inhibitors: ciclosporin, tacrolimus -antimetabolite: azathioprine, mycophenolate mofetil / mycophenolic acid, 6-mercaptopurine, methotrexate
- cyclophosphamide
- antilymphocyte serum (rabbit, horse)
- mTOR inhibitors: everolimus, sirolimus
- anti-CD25 (anti IL2-R): basiliximab, dacliximab -belatacept (anti CD80-86)
- abatacept (CTLA4-Ig)
- OKT3 (Muronomab-CD3, anti-CD23)
- glucocorticoids: methylprednisolone, prednisone, prednisolone.
- entuzumab (anti-CD52)
- rituximab, ocrelizumab (anti-CD20)
- eculizumab (anti-C5)
- anakinra (analogue IL1-RA)
- leflunomide (dihydroorotate dehydrogenase inhibition)
- bortezomib (proteasome inhibitor)
- fingolimod (S1P receptor antagonist)
- alentuzumab (anti CD52)
- Ig G -antiTNF (etanercept, infliximab, adalimumab, certolizumab)
- vedolizumab (Anti-integrin α4β7 Ab)
- ustekinumab (anti-IL12)
- natalizumab (anti-integrin a4)
- mitoxantrone (topoisomerase type II inhibitor)
- tocilizumab (anti-IL6)
Key Trial Info
Start Date :
July 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 14 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04889573
Start Date
July 7 2021
End Date
October 14 2021
Last Update
July 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Limoges University Hospital
Limoges, France, 87200